Richard John Jones, M.D.

Headshot of Richard John Jones
  • Director Bone Marrow Transplantation Program
  • Professor of Oncology
Male

Expertise

Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Aplastic Anemia, Blood Transplant, Bone Marrow Transplant, Chronic Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML), General Internal Medicine, Graft-versus-Host Disease, Hematologic Malignancies, Hematopoiesis, Hodgkin's Disease, Leukemia, Medical Oncology, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Non-Hodgkin's Lymphoma (NHL), Paroxysmal Nocturnal Hemoglobinuria ...read more

Research Interests

Bone Marrow Transplantation; Cancer Stem Cells

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231
Phone: 443-287-7104 | Fax: 410-614-7279
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Google Maps

Background

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete  his Medical Oncology Fellowship, and was then recruited to the faculty. 

Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program.

In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia.

...read more

Titles

  • Director Bone Marrow Transplantation Program
  • Co-Leader, Hematologic Malignancies and Bone Marrow Transplantation Program (HMBMT)
  • Professor of Oncology
  • Professor of Medicine

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD; Temple University School of Medicine (1978)

Residencies

  • Internal Medicine; Temple University School of Medicine (1982)

Fellowships

  • Oncology; Johns Hopkins University School of Medicine (1987)

Board Certifications

  • American Board of Internal Medicine (Internal Medicine) (1981)
  • American Board of Internal Medicine (Medical Oncology) (1987)

Research & Publications

Research Summary

My research is aimed at better understanding the biology of normal and cancer stem cells, with an eye to translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). My laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT; cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, my laboratory has found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells.

Clinical Trial Keywords

Hematologic Malignancies; Myeloid Disorders; BMT

Selected Publications

View all on PubMed

  1. Aksentijevich, I.; Jones, R.J.; Ambinder, R.F.; Garrett-Mayer, E.; Flinn, I.W. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin''s lymphoma. Biol Blood Marrow Transplant. 2006 Sep;12(9):965-972.
  2. Bolanos-Meade, J.; Hartley, E.; Jones, R.J. Long-term follow-up of allogeneic marrow transplantation for acute myelogenous leukemia after treatment with busulfan and cyclophosphamide. Biol Blood Marrow Transplant. 2006 Mar;12(3):366-367.
  3. Brodsky, R.A.; Jones, R.J. Aplastic Anemia. In: Rose, N.R.; Mackay, I.R., editors. 4th ed, The Autoimmune Diseases. Philadelphia, PA: Elsevier; 2006.
  4. Huff, C.A.; Fuchs, E.J.; Smith, B.D.; Blackford, A.; Garrett-Mayer, E.; Brodsky, R.A.; Flinn, I.W.; Ambinder, R.F.; Borrello, I.M.; Matsui, W.H.; Vogelsang, G.B.; Griffin, C.A.; Luznik, L.; Jones, R.J. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-421.
  5. Huff, C.A.; Matsui, W.; Smith, B.D.; Jones, R.J. The paradox of response and survival in cancer therapeutics. Blood. 2006 Jan 15;107(2):431-434.
  6. Huff, C.A.; Matsui, W.H.; Douglas Smith, B.; Jones, R.J. Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer. 2006 Jun;42(9):1293-1297.
  7. Matsui, W.H.; Brodsky, R.A.; Smith, B.D.; Borowitz, M.J.; Jones, R.J. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006 Mar;20(3):458-462.
  8. McNiece, I.; Civin, C.; Harrington, J.; Kellner, J.; Malehorn, M.; Turney, J.; Barber, J.; Jones, R. Ex vivo expansion of mafosfamide-purged PBPC products. Cytotherapy. 2006;8(5):459-464.
  9. Wolff, A.C.; Jones, R.J.; Davidson, N.E.; Jeter, S.C.; Stearns, V. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. J Clin Oncol. 2006 May 20;24(15):2392-2394; author reply 2394-2395.
  10. Bolanos-Meade, J.; Garrett-Mayer, E.; Luznik, L.; Anders, V.; Webb, J.; Fuchs, E.J.; Huff, C.A.; Matsui, W.; Borrello, I.M.; Brodsky, R.; Kasamon, Y.L.; Swinnen, L.J.; Flinn, I.W.; Ambinder, R.F.; Jones, R.J.; Hess, A.D.; Vogelsang, G.B. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant. 2007 Oct;13(10):1185-1191.
  11. Karp, J.E.; Smith, B.D.; Levis, M.J.; Gore, S.D.; Greer, J.; Hattenburg, C.; Briel, J.; Jones, R.J.; Wright, J.J.; Colevas, A.D. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4467-4473.
  12. Kasamon, Y.L.; Jones, R.J.; Wahl, R.L. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med. 2007 Jan;48 Suppl 1:19S-27S.
  13. Lin, T.L.; Vala, M.S.; Barber, J.P.; Karp, J.E.; Smith, B.D.; Matsui, W.; Jones, R.J. Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia. 2007 Sep;21(9):1915-1920.
  14. Petersen, S.M.; Gendelman, M.; Murphy, K.M.; Torbenson, M.; Jones, R.J.; Althaus, J.E.; Stetten, G.; Bird, C.; Blakemore, K.J. Use of T-cell antibodies for donor dosaging in a canine model of in utero hematopoietic stem cell transplantation. Fetal diagnosis and therapy. 2007;22(3):175-179.
  15. Savage, W.J.; DeRusso, P.A.; Resar, L.M.; Chen, A.R.; Higman, M.A.; Loeb, D.M.; Jones, R.J.; Brodsky, R.A. Treatment of hepatitis-associated aplastic anemia with high-dose cyclophosphamide. Pediatr Blood Cancer. 2007 Dec;49(7):947-951.
  16. Brodsky, R.A.; Jones, R.J. Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: Advantages and disadvantages. Autoimmunity. 2008 Oct 28:1.
  17. Brodsky, R.A.; Luznik, L.; Bolanos-Meade, J.; Leffell, M.S.; Jones, R.J.; Fuchs, E.J. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008 Oct;42(8):523-527.
  18. Drachman, D.B.; Adams, R.N.; Hu, R.; Jones, R.J.; Brodsky, R.A. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci. 2008;1132:305-314.
  19. Dropulic, L.K.; Jones, R.J. Polyomavirus BK infection in blood and marrow transplant recipients. Bone Marrow Transplant. 2008 Jan;41(1):11-18.
  20. Krishnan, C.; Kaplin, A.I.; Brodsky, R.A.; Drachman, D.B.; Jones, R.J.; Pham, D.L.; Richert, N.D.; Pardo, C.A.; Yousem, D.M.; Hammond, E.; Quigg, M.; Trecker, C.; McArthur, J.C.; Nath, A.; Greenberg, B.M.; Calabresi, P.A.; Kerr, D.A. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol. 2008 Aug;65(8):1044-1051.
  21. Luznik, L.; O''Donnell, P.V.; Symons, H.J.; Chen, A.R.; Leffell, M.S.; Zahurak, M.; Gooley, T.A.; Piantadosi, S.; Kaup, M.; Ambinder, R.F.; Huff, C.A.; Matsui, W.; Bolanos-Meade, J.; Borrello, I.; Powell, J.D.; Harrington, E.; Warnock, S.; Flowers, M.; Brodsky, R.A.; Sandmaier, B.M.; Storb, R.F.; Jones, R.J.; Fuchs, E.J. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun;14(6):641-650.
  22. Matsui, W.; Wang, Q.; Barber, J.P.; Brennan, S.; Smith, B.D.; Borrello, I.; McNiece, I.; Lin, L.; Ambinder, R.F.; Peacock, C.; Watkins, D.N.; Huff, C.A.; Jones, R.J. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008 Jan 1;68(1):190-197.
  23. Warlick, E.D.; O''Donnell, P.V.; Borowitz, M.; Grupka, N.; Decloe, L.; Garrett-Mayer, E.; Borrello, I.; Brodsky, R.; Fuchs, E.; Huff, C.A.; Luznik, L.; Matsui, W.; Ambinder, R.; Jones, R.J.; Douglas Smith, B. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. 2008 Sep;32(9):1439-1447.
  24. Bolanos-Meade, J.; Luznik, L.; Muth, M.; Matsui, W.H.; Huff, C.A.; Smith, B.D.; Levy, M.Y.; Kasamon, Y.L.; Swinnen, L.J.; Powell, J.D.; Brodsky, R.A.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009 Mar;43(6):477-480.
  25. Emadi, A.; Jones, R.J.; Brodsky, R.A. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009 Nov;6(11):638-647.
  26. Fuchs, E.J.; Luznik, L.; Bolanos-Meade, J.; Miller, C.B.; Brodsky, R.A.; Ambinder, R.F.; Jones, R.J. Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. Bone Marrow Transplant. 2009 Jun;43(12):969-970.
  27. Hu, R.; Mukhina, G.L.; Lee, S.H.; Jones, R.J.; Englund, P.T.; Brown, P.; Sharkis, S.J.; Buckley, J.T.; Brodsky, R.A. Silencing of genes required for glycosylphosphatidylinositol anchor biosynthesis in Burkitt lymphoma. Exp Hematol. 2009 Apr;37(4):423-434 e422.
  28. Huang, Y.; Stewart, T.M.; Wu, Y.; Baylin, S.B.; Marton, L.J.; Perkins, B.; Jones, R.J.; Woster, P.M.; Casero, R.A., Jr. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res. 2009 Dec 1;15(23):7217-7228.
  29. Jones, R.J. Controversies in cancer stem cells. J Mol Med. 2009 Oct 23;87(11):1077-1078.
  30. Jones, R.J. Cancer stem cells-clinical relevance. J Mol Med. 2009 Oct 10;87(11):1105-1110.
  31. Jones, R.J.; Gocke, C.D.; Kasamon, Y.L.; Miller, C.B.; Perkins, B.; Barber, J.P.; Vala, M.S.; Gerber, J.M.; Gellert, L.L.; Siedner, M.; Lemas, M.V.; Brennan, S.; Ambinder, R.F.; Matsui, W. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood. 2009 Jun 4;113(23):5920-5926.
  32. Kasamon, Y.L.; Luznik, L.; Leffell, M.S.; Kowalski, J.; Tsai, H.L.; Bolanos-Meade, J.; Morris, L.E.; Crilley, P.A.; O''Donnell, P.V.; Rossiter, N.; Huff, C.A.; Brodsky, R.A.; Matsui, W.H.; Swinnen, L.J.; Borrello, I.; Powell, J.D.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative HLA-Haploidentical BMT with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. Biol Blood Marrow Transplant. 2009 Nov 16.
  33. Kasamon, Y.L.; Wahl, R.L.; Ziessman, H.A.; Blackford, A.L.; Goodman, S.N.; Fidyk, C.A.; Rogers, K.M.; Bolanos-Meade, J.; Borowitz, M.J.; Ambinder, R.F.; Jones, R.J.; Swinnen, L.J. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant. 2009 Feb;15(2):242-248.
  34. Savage, W.J.; Barber, J.P.; Mukhina, G.L.; Hu, R.; Chen, G.; Matsui, W.; Thoburn, C.; Hess, A.D.; Cheng, L.; Jones, R.J.; Brodsky, R.A. Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Exp Hematol. 2009 Jan;37(1):42-51.
  35. Bolanos-Meade, J.; Smith, B.D.; Gore, S.D.; McDevitt, M.A.; Luznik, L.; Fuchs, E.J.; Jones, R.J. 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2010 Oct 15;In Press.
  36. Brennan, S.K.; Wang, Q.; Tressler, R.; Harley, C.; Go, N.; Bassett, E.; Huff, C.A.; Jones, R.J.; Matsui, W. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One. 2010;5(9).
  37. Brodsky, R.A.; Chen, A.R.; Dorr, D.; Fuchs, E.J.; Huff, C.A.; Luznik, L.; Smith, B.D.; Matsui, W.H.; Goodman, S.N.; Ambinder, R.F.; Jones, R.J. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18;115(11):2136-2141.
  38. Dezern, A.E.; Luznik, L.; Fuchs, E.J.; Jones, R.J.; Brodsky, R.A. Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant. 2010 Sep 13.
  39. Jones, R.; Lebkowski, J.; McNiece, I. Stem cells. Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S115-118.
  40. Karp, J.E.; Blackford, A.; Smith, B.D.; Alino, K.; Seung, A.H.; Bolanos-Meade, J.; Greer, J.M.; Carraway, H.E.; Gore, S.D.; Jones, R.J.; Levis, M.J.; McDevitt, M.A.; Doyle, L.A.; Wright, J.J. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res. 2010 Jul;34(7):877-882.
  41. Kasamon, Y.L.; Jones, R.J.; Brodsky, R.A.; Fuchs, E.J.; Matsui, W.; Luznik, L.; Powell, J.D.; Blackford, A.L.; Goodrich, A.; Gocke, C.D.; Abrams, R.A.; Ambinder, R.F.; Flinn, I.W. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol. 2010 Jun;21(6):1203-1210.
  42. Kasamon, Y.L.; Jones, R.J.; Gocke, C.D.; Blackford, A.L.; Seifter, E.J.; Davis-Sproul, J.M.; Gore, S.D.; Ambinder, R.F. Extended Follow-Up of Autologous Bone Marrow Transplantation with 4-Hydroperoxycyclophosphamide (4-HC) Purging for Indolent or Transformed Non-Hodgkin''s Lymphomas. Biol Blood Marrow Transplant. 2010 Jul 21.
  43. Kasamon, Y.L.; Luznik, L.; Leffell, M.S.; Kowalski, J.; Tsai, H.L.; Bolanos-Meade, J.; Morris, L.E.; Crilley, P.A.; O''Donnell, P.V.; Rossiter, N.; Huff, C.A.; Brodsky, R.A.; Matsui, W.H.; Swinnen, L.J.; Borrello, I.; Powell, J.D.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr;16(4):482-489.
  44. Luznik, L.; Bolanos-Meade, J.; Zahurak, M.; Chen, A.R.; Smith, B.D.; Brodsky, R.; Huff, C.A.; Borrello, I.; Matsui, W.; Powell, J.D.; Kasamon, Y.; Goodman, S.N.; Hess, A.; Levitsky, H.I.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-3230.
  45. Luznik, L.; Jones, R.J.; Fuchs, E.J. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol. 2010 Nov;17(6):493-499.
  46. Peltonen, K.; Colis, L.; Liu, H.; Jaamaa, S.; Moore, H.M.; Enback, J.; Laakkonen, P.; Vaahtokari, A.; Jones, R.J.; af Hallstrom, T.M.; Laiho, M. Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS One. 2010;5(9):e12996 Not supported through NIH funding.
  47. Petri, M.; Brodsky, R.A.; Jones, R.J.; Gladstone, D.; Fillius, M.; Magder, L.S. High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum. 2010 May;62(5):1487-1493.
  48. Sharrow, A.C.; Ronnett, B.M.; Thoburn, C.J.; Barber, J.P.; Giuntoli, R.L., 2nd; Armstrong, D.K.; Jones, R.J.; Hess, A.D. Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats. J Ovarian Res. 2010;3:9.
  49. Smith, B.D.; Kasamon, Y.L.; Kowalski, J.; Gocke, C.; Murphy, K.; Miller, C.B.; Garrett-Mayer, E.; Tsai, H.L.; Qin, L.; Chia, C.; Biedrzycki, B.; Harding, T.C.; Tu, G.H.; Jones, R.; Hege, K.; Levitsky, H.I. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010 Jan 1;16(1):338-347.
  50. Symons, H.J.; Leffell, M.S.; Rossiter, N.D.; Zahurak, M.; Jones, R.J.; Fuchs, E.J. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2010 Apr;16(4):533-542.
  51. Smith, B.D.; Jones, R.J.; Cho, E.; Kowalski, J.; Karp, J.E.; Gore, S.D.; Vala, M.; Meade, B.; Baker, S.D.; Zhao, M.; Piantadosi, S.; Zhang, Z.; Blumenthal, G.; Warlick, E.D.; Brodsky, R.A.; Murgo, A.; Rudek, M.A.; Matsui, W.H. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res. 2011 Jan;35(1):87-94.
Is this you? Edit Profile
back to top button